Picture supply: Getty Photographs
Oxford Nanopore Applied sciences (LSE:ONT) is an thrilling FTSE 250 inventory and is massively undervalued in keeping with analysts. Nevertheless, regardless of its groundbreaking expertise and up to date collaborations, the inventory has slumped. Not like a lot of its friends, the hunch truly has little or no to do with Donald Trump’s tariffs.
A DNA pioneer
For these unfamiliar, Oxford Nanopore is a pioneer in third-generation DNA sequencing expertise. The corporate’s gadgets use nanopores — these are tiny protein-based buildings — to sequence DNA or RNA in actual time by detecting electrical adjustments as molecules go by these pores. This expertise is all out there on handheld gadgets.
Its expertise is used throughout a number of fields, starting from infectious illness evaluation to genomic surveillance in distant places. As an example, its gadgets had been used throughout the Ebola outbreak in 2015 to sequence viral genomes quickly.
Nevertheless, issues haven’t gone to plan since itemizing in late 2021. Oxford Nanopore’s share worth has plummeted by over 80%, decreasing its market capitalisation to over £1bn. This dramatic decline stems from a mixture of things, together with persistent losses, heightened competitors, and macroeconomic challenges similar to rising rates of interest. Analysts have additionally flagged considerations about slower-than-expected progress and a worsening funding setting.
Analysts name this a ‘Robust Purchase’
Regardless of the collapsing share worth, analysts appear remarkably bullish. Of the ten analysts masking the inventory, 4 have Purchase rankings and 4 have Outperform rankings. What’s extra, the typical share worth goal is now 69% increased than the present share worth. That is sometimes a very good signal. By the way, the very best share worth goal is 138% above the place we’re right this moment.
Nevertheless, shrewd buyers might want to query this name. The corporate’s working loss has practically doubled to £152m since 2019, and the forecast suggests it gained’t attain adjusted EBITDA breakeven till 2027. For 2025, analysts anticipated damaging earnings per share (EPS) of 15.9p. That’s not insignificant for inventory valued at 114p per share.
The saving grace is the web money place which at present stands at £292m and is ready to fall to £158m by the top of 2026 based mostly on the forecast. Which means it does have some runway till its long-awaited profitability.
After all, it might not attain profitability in its present state. Ongoing losses and a falling share worth have made the inventory susceptible, with some suggesting it may change into a takeover goal for bigger gamers like Thermo Fisher Scientific or Danaher.
The underside line
On 9 April 2025, Oxford Nanopore introduced a strategic collaboration with Cepheid to develop automated sequencing options for infectious ailments. The may develop into different areas like most cancers diagnostics and human genetics, doubtlessly opening new income streams.
Nevertheless, buyers needs to be cautious that Oxford Nanopore is a traditional high-risk, high-reward funding. Its modern expertise and strategic collaborations place it nicely for future progress, however I’m reluctant to throw my very own cash behind it. Nonetheless, I’ll proceed to maintain an in depth eye on developments.
